Chercheur dans l'institut de recherche contre le cancer

Supported projects

The cluster provides access to the best oncology skills, tools, and services for the most promising projects led by organizations of varying sizes and maturity. The PSCC takes a selective approach, focusing its resources where they can have the greatest impact. We evaluate projects at different stages of maturity based on the quality of their team, scientific strength, development opportunities, and their alignment with the cluster's objectives. Our rigorous selection process involves an independent evaluation committee composed of experienced scientists and industry leaders.

Supported projects

They were accompanied

Projects filters (+70)

Abbelight's project to develop a liquid biopsy diagnostic technology combining super-resolution microscopy, extracellular vesicles and artificial intelligence. This approach improves the detection and analysis of circulating biomarkers, offering greater precision for the early diagnosis and monitoring of diseases, particularly in oncology. By integrating these advances, the solution optimises precision medicine and opens up new prospects for more targeted and effective treatments.

France

Île-de-France

Medtech

TechBio

Medtech - Development

Abbelight

Abcely is developing an innovative immunotherapy based on orally administered IgA monoclonal antibodies, targeting cancers of the digestive mucosa and endometriosis. Thanks to their polymeric structure, IgA antibodies are more avid for their target and recruit neutrophils more effectively. A unique platform for the identification, optimisation and production of these antibodies, offering an alternative to intravenous or subcutaneous IgG treatments.

France

Pays de la Loire

Biotech

Immunotherapy

Biotech - Pre-IND/Pre-CTA

Lauréat

iLAB

Abcely

Specializes in the discovery of biomarkers and the development of innovative medical diagnostics for precision medicine. In particular, it is developing GEMCITEST®, a blood test that predicts patient response to gemcitabine as a first-line treatment.

France

Occitanie

Medtech

DM/DiV

Medtech - Approval

Acobiom

Biotech développant une plateforme universelle de thérapie cellulaire de nouvelle génération basée sur des cellules T précurseurs (pre-T), permettant des immunothérapies « off-the-shelf » plus sûres et plus accessibles pour les tumeurs solides, avec une forte pertinence en oncologie pédiatrique et chez les jeunes adultes.

France

Auvergne-Rhône-Alpes

Biotech

Cell & Gene therapy

Biotech - Pre-IND/Pre-CTA

Lauréat

iLAB

Allogenica

Is developing a portfolio of first-in-class peptides targeting the tumour microenvironment. Its most advanced programme, AP-01, is a cyclic peptide inhibiting TSP-1, a ligand of the CD47 receptor, in various tumour indications with a high medical need. Other promising programmes targeting the extracellular matrix are also in development.

France

Grand Est

Biotech

Targeted therapy

Biotech - Pre-IND/Pre-CTA

Lauréat

iLAB, iNov, EIC laureate

Apmonia Therapeutics

Based on the discovery of the role of the transmembrane receptor Tmem176b in the regulation of tumour inflammation. It is developing compounds targeting this receptor to reactivate inflammation and boost anti-tumour activity, particularly in melanoma, colorectal cancer and chronic lymphatic leukaemia.

Argentina

Santa Fe

Biotech

Immunotherapy

Biotech - Lead optimization

ARDAN Pharma

Develops drugs targeting the mutated DNA that causes serious diseases, with a particular focus on paediatric tumours. Using its proprietary MyGenera™ platform, the company rapidly identifies and designs ultra-specific therapies tailored to each patient. This revolutionary approach opens up new prospects for treating hitherto incurable pathologies.

Italy

Bologna

Biotech

Cell & Gene therapy

Biotech - Pre-IND/Pre-CTA

Biogenera

Specializing in the development of innovative cell therapies - chimeric antigen receptor T cells (CAR-T), T cell receptor T cells (TCR-T) and tumor-infiltrating lymphocytes (TIL) - for the treatment of cancer.

Singapore

Biotech

Cell & Gene therapy

Biotech - Phase 2

BioSyngen

A biotech developing first-in-class oral small molecule targeting BiP, a key protein involved in cancer cells survival and associated with poor prognosis when overexpressed in tumors and in plasma of patients. The start-up targets BIP+ patients through precision medicine approach.

France

Grand Est

Biotech

Targeted therapy

Pre-IND/Pre-CTA

Biper Therapeutics

Blue Bees is developing first-in-class immunotherapies based on a breakthrough technology exploiting dual targeting of cell receptors coupled to heparan sulphate proteoglycans (HSPGs). This innovative approach aims to boost the anti-tumour immune response and open up new therapeutic prospects.

France

Île-de-France

Biotech

Immunotherapy

Biotech - Pre-IND/Pre-CTA

Blue Bees Therapeutics

Develops next-generation allogeneic immunotherapies to prevent cancer recurrence, the main challenge in solid tumours. Using its patented technology platform, the company designs first-in-class therapeutic vaccines targeting tumour antigens and educating the immune system to overcome tumour resistance. Its lead candidate, a proteomic immunotherapy, targets colorectal cancer, the second most common cause of cancer deaths worldwide.

France

Auvergne-Rhône-Alpes

Biotech

Immunotherapy

Biotech - Pre-IND/Pre-CTA

Lauréat

iLAB

Brenus Pharma

A preclinical stage biotech developing a pipeline of precision immunotherapies for severe and aggressive diseases based on a fully integrated adaptive CAR-T platform plug-and-play technology.

France

Bourgogne Franche Comté

Biotech

Cell & Gene therapy

Biotech - Pre-IND/Pre-CTA

Lauréat

iLAB

Carla Biotherapeutics

Aims to develop a platform for the genetic engineering of autologous monocytes to boost anti-tumour immunity, with an approach aimed at designing personalized cell therapies and enabling the rapid and effective reinfusion of modified monocytes to fight cancer.

France

Île-de-France

Biotech

Cell & Gene therapy

Biotech - Discovery

CedraTherapeutics

Is developing a real-time surgical guidance technology combining laser, mass spectrometry and artificial intelligence. Its innovative system enables precise identification of tumour tissue and surgical margins, optimising tumour removal while preserving healthy tissue. The aim of this approach is to reduce the risk of relapse and improve the outcome of oncology operations.

France

Hauts de France

Medtech

Medtech - Development

Lauréat

iLAB

Celeos

Focused on the manufacturing of breakthrough cell therapies. Their bioreactor with unique properties (controlled shear forces, homogeneity, easy scale-up, etc.) meets the challenges of expanding induced pluripotent stem (iPS) cells.

France

Provence-Alpes-Côte d'Azur

Medtech

TechBio

Medtech - Laboratory PoC

Cellura

Cherry Biotech markets a technological platform integrating cellular engineering, microfluidics, artificial intelligence and advanced imaging to recreate 3D human models (organs on a chip). Its aim is to anticipate the impact of treatments on the body, particularly for orphan diseases, cancer and bacterial resistance. Its patented CUBIX technology makes it possible to grow complex, vascularized tissue models, offering an ethical and innovative alternative to animal testing, while integrating into current industrial workflows.

France

Île-de-France

Medtech

TechBio

Medtech – Market

Lauréat

iLAB, EIC laureate

Cherry Biotech

Supported projects

Apply with your project

Passed Projects filters

Spin-off de l’Institut Curie, Emglev Therapeutics utilise sa plateforme propriétaire unique d'anticorps synthétiques de nouvelle génération pour découvrir et développer des immunothérapies transformatrices afin de répondre aux besoins médicaux non satisfaits en oncologie. Emglev Therapeutics a été acquise par Valerio Therapeutics en septembre 2024, dont elle est désormais une filiale sous le nom de Valour Bio.

France

Île-de-France

Biotech

Cell & Gene therapy

Biotech - Lead optimization

Emglev Therapeutics

Start-up qui crée une plateforme SaaS utilisant le traitement du langage naturel (NLP) et l'apprentissage automatique (ML) afin d'automatiser la collecte et l'utilisation des données non structurées pertinentes en oncologie. Gimli a été rachetée en novembre 2024 par Resilience.

France

Île-de-France

Medtech

e-health

Medtech - Development

GIMLI

Développe un test diagnostique in vitro basé sur le microbiome, marqué CE, pour prédire la réponse aux inhibiteurs de points de contrôle immunitaire.

France

Île-de-France

Medtech

DM/DiV

Medtech - Development

GMT Science

Met au point une technologie d’imagerie médicale de nouvelle génération basée sur l’IRM QUTE-CE, qui fournit des biomarqueurs vasculaires en haute résolution. Cette approche non invasive permet d’évaluer avec précision la structure et la fonction des petits vaisseaux sanguins dans tout le corps, offrant aux cliniciens et chercheurs de nouveaux outils pour la détection précoce et la caractérisation des maladies complexes, notamment le cancer.

USA

Florida

Medtech

Medtech - Development

Imaginostics

Développe PT-112, un agent anti-cancéreux innovant induisant la mort cellulaire immunogène. Ciblant la biogenèse des ribosomes, ce candidat médicament favorise une réponse immunitaire anti-tumorale en activant les lymphocytes T cytotoxiques. PT-112 a montré des résultats prometteurs en combinant un traitement direct de la tumeur avec une stimulation de l’immunité anti-cancéreuse, ouvrant la voie à des solutions thérapeutiques novatrices contre les cancers solides et hématologiques.

USA

New York

Biotech

Targeted therapy

Biotech - Phase 2

Promontory Therapeutics

Développe des microrobots miniaturisés pour la neurochirurgie, permettant de réaliser des biopsies, délivrer des traitements et effectuer un suivi post-opératoire dans des zones difficiles d’accès du corps. Grâce à des technologies avancées de robotique et d’intelligence artificielle, ces microrobots offrent une précision accrue et s’adaptent à diverses applications médicales pour des traitements plus efficaces et moins invasifs.

France

Île-de-France

Medtech

Medtech - Development

Lauréat

EIC

Supported projects

Projects filters (+70)

Abbelight

Abcely

Acobiom

Allogenica

Apmonia Therapeutics

ARDAN Pharma

Biogenera

BioSyngen

Biper Therapeutics

Blue Bees Therapeutics

Brenus Pharma

Carla Biotherapeutics

CedraTherapeutics

Celeos

Cellura

Cherry Biotech

Supported projects

Passed Projects filters

Emglev Therapeutics

GIMLI

GMT Science

Imaginostics

Promontory Therapeutics

Robeauté

They were accompanied

Ecosystem

News

Legal notices

Contact